Obe-cel demonstrates strong efficacy and safety in treating leukemia

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.

Capstan Medical raises $110M for heart valve with robotic system

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Capstan Medical, which is developing

December 12, 2024

Genentech, Gilead push FDA to modernize research inspections

Roche’s Genentech, Gilead, Sanofi and other drugmakers weighed in on the FDA’s recent draft guidance on research inspections, with the companies calling for clarity and

August 10, 2024

Yes, It Matters Who Manages Sedation During Interventional Radiology Procedures

SAN FRANCISCO — Following interventional radiology procedures such as coronary angioplasty, patients were more likely to be discharged home, rather than to a nursing or

October 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.